PDCD1 and neoplasm: Several anti-PD-1 and anti-PD-L1 antibodies are now approved as single-agents and in combination with other drugs for the treatment of multiple tumor types including lung cancer, melanoma, renal cell carcinoma, hepatocellular carcinoma, and others (20, 21).